Share

February 15, 2022; 98 (7) Research Article

Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination

Katarzyna Krzywicka, Anita van de Munckhof, Mayte Sánchez van Kammen, Mirjam R. Heldner, Katarina Jood, Erik Lindgren, Turgut Tatlisumak, Jukka Putaala, Johanna A. Kremer Hovinga, Saskia Middeldorp, Marcel M. Levi, Charlotte Cordonnier, Marcel Arnold, Aeilko H. Zwinderman, José M. Ferro, Jonathan M. Coutinho, Diana Aguiar de Sousa
First published December 17, 2021, DOI: https://doi.org/10.1212/WNL.0000000000013148
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
205

Share

Article Information

vol. 98 no. 7 e759-e768
DOI: 
https://doi.org/10.1212/WNL.0000000000013148
PubMed: 
34921101
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 24, 2021
  • Accepted in final form November 23, 2021
  • First Published December 17, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Katarzyna Krzywicka, MD, MPhil*,
    2. Anita van de Munckhof, MD*,
    3. Mayte Sánchez van Kammen, MD,
    4. Mirjam R. Heldner, MD, MSc,
    5. Katarina Jood, MD, PhD,
    6. Erik Lindgren, MD,
    7. Turgut Tatlisumak, MD, PhD,
    8. Jukka Putaala, MD, PhD,
    9. Johanna A. Kremer Hovinga, MD,
    10. Saskia Middeldorp, MD, PhD,
    11. Marcel M. Levi, MD, PhD,
    12. Charlotte Cordonnier, MD, PhD,
    13. Marcel Arnold, MD,
    14. Aeilko H. Zwinderman, MD, PhD,
    15. José M. Ferro, MD, PhD,
    16. Jonathan M. Coutinho, MD, PhD† and
    17. Diana Aguiar de Sousa, MD, PhD†
  1. Katarzyna Krzywicka, MD, MPhil*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Anita van de Munckhof, MD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Mayte Sánchez van Kammen, MD,
    4. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Mirjam R. Heldner, MD, MSc,
    5. Scientific Advisory Boards:

    1. Scientific advisory board honoraria from Amgen, not directly related to this manuscript.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel support from Bayer, not directly related to this manuscript.

    Editorial Boards:

    1. Being a member of the ESO Board of Directors and of the ESO Education Committee, not directly related to this manuscript.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Grants from the Bangerter Foundation and the Swiss Heart Foundation, not directly related to this manuscript.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Katarina Jood, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. the Swedish State under the ALF agreement (ALFGBG-720211), and Region Västra Götaland (VGFOUREG-662151)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Research grants from (1) The John and Brit Wennerströms Foundation, (2) The Per-Olof Ahl Foundation, Peter Erikssons Foundation, and (3) The Rune and Ulla Amlöv Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Erik Lindgren, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Research grants from (1) The Swedish Neurological Society, (2) Elsa and Gustav Lindh's Foundation, (3) P-o Ahl's Foundation, (4) Rune and Ulla Amlöv's Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Turgut Tatlisumak, MD, PhD,
    8. Scientific Advisory Boards:

    1. Bayer, Bristol Myers Squibb, Portola Pharm

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Congress traveling and accommodation costs (none commercial): European Stroke Organisation University of Donau (Austria) 2nd Stroke Academy Meeting, Istanbul, Turkey

    Editorial Boards:

    1. Current Vascular Pharmacology, 2002- Stroke Research and Treatment, 2009- Frontiers in Stroke, 2010- European Stroke Journal, 2016- Therapeutic Advances in Neurological Disorders, 2017- No compensation was received for any of the above editorial duties

    Patents:

    1. 1. New Therapeutic Uses (method to prevent brain edema and reperfusion injury), PCT/FI2004/000070. Inventors: Lindsberg PJ, Karjalainen-Lindsberg M-L, Tatlisumak T, Strbian D. Applicant: Licentia Oy. Application date: February 13, 2003. Publication 7/2003, Application number: 20030224. 2. Thrombolytic compositions (method to prevent postthrombolytic hemorrhage formation), PCT/FI2004/000071. Inventors: Lindsberg PJ, Karjalainen- Lindsberg M-L, Tatlisumak T, Strbian D, Kovanen P. Applicant: Licentia Oy. Application date: February 13, 2003. Publication: 3/2003. Application number: 20030225.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. University of Gothenburg Research Funds, PI Sahlgrenska University Hospital Research Funds, PI European Union

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Wennerströms Foundation, PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Jukka Putaala, MD, PhD,
    9. Scientific Advisory Boards:

    1. (1) Advisory Board: Boehringer-Ingelheim (2) Advisory Board: Bayer (3) Advisory Board: BMS-Pfizer (4) Advisory Board: Portola (5) Advisory Board: Herantis Pharma

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Speaker honoraria: Boehringer-Ingelheim (2) Speaker honoraria: Bayer (3) Speaker honoraria: BMS-Pfizer (4) Speaker honoraria: Abbott

    Editorial Boards:

    1. (1) European Stroke Journal: Member of the Editorial Board (2) Terve Media: Visiting Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Trial site-PI: Bayer (2) Trial site-PI: Amgen

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Nonrestricted grant from Pfizer

    Research Support, Government Entities:

    1. (1) Helsinki-Uusimaa Hospital District, PI (2) Academy of Finland, PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Finnish Foundation for Cardiovascular Research Stock/Stock Options, Medical Equipment & Materials: (1) Stock ownership: Vital Signum

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Johanna A. Kremer Hovinga, MD,
    10. Scientific Advisory Boards:

    1. 1) Takeda 2) Ablynx/Sanofi

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1) Haemostaseologie, Advisory/Editorial Board, 9y 2) Thrombosis Journal, Editorial Board, 9y 3) Research and Practice in Thrombosis and Haemostasis, Editorial Board, 6y 4) HemaSphere, Editorial Board, 3y 5) Haematologica, Editorial Board, 1y

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. All Honroaria go to my employer, INSEL Gruppe AG (Bern University Hospital) 1) CSL Behring 2) NovoNordisk 3) Roche 4) Federal Bureau of Public Health (FOPH) Switzerland

    Speakers' Bureaus:

    1. All Honroaria go to my employer, INSEL Gruppe AG (Bern University Hospital) 1) CSL Behring 2) NovoNordisk 3) Roche

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Unresistrcted research grant from Baxter/Takeda for the International Hereditary Thrombotic Thrombocytopenic Purpura Registry 2) Interprofessional Hemophilia Care at EHCCC Inselspital is supported by grants from Bayer, CSL Behring, NovoNordisk, Octapharma, Sobi, and Roche

    Research Support, Government Entities:

    1. Swiss National Science Foundation (Grant 310030-185233); PI; 07/2019 – 06/2022; topic: “Thrombotic thrombocytopenic purpura – the role of ADAMTS13 and long-term outcome”

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Saskia Middeldorp, MD, PhD,
    11. Scientific Advisory Boards:

    1. Bayer, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Portola: advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Marcel M. Levi, MD, PhD,
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. J Thrombosis Hemostasis Thrombosis Research Eur J Int Med Seminars Thrombosis Hemostasis ALL UNCOMPENSATED

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Charlotte Cordonnier, MD, PhD,
    13. Scientific Advisory Boards:

    1. BMS, steering committee (ongoing) Biogen, steering committee (ongoing) Astra-Zeneca, advisory board (on secondary prevention after minor strokes)- terminated University of Glasgow, DSMB (unpaid-ongoing)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Stroke, Associate editor, 2020-ongoing

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. French ministry of health, PHRC A3ICH, PI, 2016-ongoing

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Marcel Arnold, MD,
    14. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. J Thrombosis HemostasisThrombosis ResearchEur J Int MedSeminars Thrombosis HemostasisALL UNCOMPENSATED

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Aeilko H. Zwinderman, MD, PhD,
    15. Scientific Advisory Boards:

    1. (1) commerical: DSMB membership of a study organized by Torrent Pharmaceutical (India) on a a new compound for cardiovascular diseases

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. José M. Ferro, MD, PhD,
    16. Scientific Advisory Boards:

    1. Boehringer Ingelheim

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Boehringer Ingelheim

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Boehringer Ingelheim, Bayer

    Speakers' Bureaus:

    1. Boehringer Ingelheim

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Jonathan M. Coutinho, MD, PhD† and
    17. Scientific Advisory Boards:

    1. (1) Boehringer Ingelheim, Bayer, Portola and Medtronic. All fees were paid to my employer, Amsterdam University Medical Centers, and were used to fund academic research.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Stroke, Editorial Board Member, 2017-now (2) Journal of Neurology, Editorial Board member 2021-now (3) Frontiers in Neurology, associate Editor, 2020-now (4) BMC Neurology, Associate Editor, 2018-2019

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) ZonMw, grant number 10430072110005, 2021

    Research Support, Academic Entities:

    1. (1) Dr. C.J. Vaillant Fonds

    Research Support, Foundations and Societies:

    1. (1) Dutch Heart Foundation (2) Dutch Thrombosis Foundation (3) Health Holland (4) EU funding (Eurostars)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Diana Aguiar de Sousa, MD, PhD†
    18. Scientific Advisory Boards:

    1. (1) Sponsor: Dr. Thalia Field; Funders: Canadian Institutes of Health Research, Canadian Stroke Consortium, and Heart and Stroke Foundation of Canada; Study of rivaroxaban for CeREbral venous Thrombosis (SECRET trial); Data Safety Monitoring Board member. (2) Advisory Board participation for Astrazeneca

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Boehringer Ingelheim, nonfinancial support outside of the submitted work (travel expenses)

    Editorial Boards:

    1. Stroke (AHA/ASA journals), member of the editorial board, 2019 Stroke (AHA/ASA journals), assistant editor, 2019 European Stroke Journal, member of the editorial board, since 2019

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Fundação para Ciência e Tecnologia, SFRH/SINTD/92677/2013, PhD student, 2014-2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Fundação AstraZeneca, 11º Bolsa de Investigação Fundação AstraZeneca - Faculdade de Medicina Universidade de Lisboa (2) Fundação Amélia de Mello, D. Manuel de Mello grant

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neurology (K.K., A.v.d.M., M.S.v.K., J.M.C.) and Vascular Medicine (M.M.L.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; Departments of Neurology (M.R.H., M.A.) and Hematology (J.A.K.H.), Inselspital, Bern University Hospital, University of Bern; Department of Neurology (K.J., E.L., T.T.), Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J., E.L., T.T.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Neurology (J.P.), Helsinki University Hospital and University of Helsinki, Finland; Department of Internal Medicine (S.M.) and Radboud Institute of Health Sciences (S.M.), Radboud University Medical Center, Nijmegen, the Netherlands; National Institute for Health Research University College London Hospitals Biomedical Research Centre (M.M.L.), UK; University of Lille (C.C.), Inserm, CHU Lille, U1172–Lille Neuroscience and Cognition, France; Department of Clinical Epidemiology and Biostatistics (A.H.Z.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; and Department of Neurosciences and Mental Health (J.M.F., D.A.d.S.), Neurology Service, Hospital de Santa Maria/Centro Hospitalar Universitário Lisboa Norte (CHULN), University of Lisbon, Portugal.
  1. Correspondence
    Dr. Aguiar de Sousa dianasousa{at}campus.ul.pt
View Full Text

Article usage

Article usage: December 2021 to June 2022

AbstractFullPdfSource
Dec 20212432044Highwire
Jan 2022636017Highwire
Feb 2022140416478Highwire
Mar 20225587733Highwire
Apr 20222642111Highwire
May 20222602616Highwire
Jun 2022199146Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Alert Me